Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients

  • Original Article
  • Published:
Tumor Biology

Abstract

The abnormal expression of microRNA-221 was detected in several cancers and some studies had indicated that microRNA-221 was associated with cancer prognosis. This study was aimed to evaluate the prognostic significance of microRNA-221 in non-small cell lung cancer (NSCLC). Quantitative real-time polymerase chain reaction (qRT-PCR) was used for detecting the relative expression levels of microRNA-221 in the pathological tissues and corresponding normal tissues of 104 NSCLC patients. The relationship between the expression levels and the clinical features was estimated by Chi-square method and the overall survival of patients at different expression levels was demonstrated by Kaplan-Meier method. Cox regression analysis was used to evaluate the prognostic significance of microRNA-221. The relative expression levels of microRNA-221 in the pathological tissues were remarkably higher than that in the corresponding normal tissues (1.71 vs 1.07, P = 0.000). The expression level was associated with lymph node metastasis (P = 0.001). The results of Kaplan-Meier method indicated that patients with high expression level of microRNA-221 had shorter overall survival time than those with low expression level (36.8 vs 45.2 months, P = 0.001). Moreover, Cox regression analysis suggested that microRNA-221 was a useful independent biomarker for NSCLC prognosis (HR = 1.873, 95 % CI = 1.267-2.768, P = 0.002). The aberrant expression of microRNA-221 is associated with NSCLC progression and it might be a potential biomarker for NSCLC prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355–67. doi:10.4065/83.3.355.

    Article  CAS  PubMed  Google Scholar 

  3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. doi:10.4065/83.5.584.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw. 2015;13(5):515–24.

    Google Scholar 

  5. Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, et al. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol. 2011;22(2):376–82. doi:10.1093/annonc/mdq360.

    Article  CAS  PubMed  Google Scholar 

  6. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One. 2011;6(11):e26646. doi:10.1371/journal.pone.0026646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ke Z, He W, Lai Y, Guo X, Chen S, Li S, et al. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. Oncotarget. 2014;5(19):9410–24.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  9. Simonson B, Das S. MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem. 2015;15(6):467–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chung AC, Lan HY. MicroRNAs in renal fibrosis. Front Physiol. 2015;6:50. doi:10.3389/fphys.2015.00050.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Yan S, Cao Y, Mao A. MicroRNAs in colorectal cancer: potential biomarkers and therapeutic targets. Front Biosci (Landmark Ed). 2015;20:1092–103.

    Article  Google Scholar 

  12. Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2014;20(24):7894–913. doi:10.3748/wjg.v20.i24.7894.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yang F, Zhang W, Shen Y, Guan X. Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol. 2015;46(3):927–32. doi:10.3892/ijo.2015.2821.

    CAS  PubMed  Google Scholar 

  14. Ke J, Zhao Z, Hong SH, Bai S, He Z, Malik F, et al. Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. Oncotarget. 2015;6(6):3709–21.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett. 2014;588(1):99–104. doi:10.1016/j.febslet.2013.11.014.

    Article  CAS  PubMed  Google Scholar 

  16. Sun X, Liu B, Zhao XD, Wang LY, Ji WY. MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1. Oncol Rep. 2015;33(3):1221–6. doi:10.3892/or.2015.3714.

    CAS  PubMed  Google Scholar 

  17. Xu Y, Zhong C, Ding S, Huang H, Shen Z. MicroRNA-221 promotes human non-small cell lung cancer cell H460 growth. Int J Clin Exp. 2015;8(2):2024–30.

    CAS  Google Scholar 

  18. Brighenti M. MicroRNA and MET in lung cancer. Ann Transl Med. 2015;3(5):68. doi:10.3978/j.issn.2305-5839.2015.01.26.

    PubMed  PubMed Central  Google Scholar 

  19. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293–302. doi:10.1038/nrc2619.

    Article  CAS  PubMed  Google Scholar 

  20. Peng Y, Dong W, Lin TX, Zhong GZ, Liao B, Wang B, et al. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget. 2015;6(18):16043–58.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Liu S, Pan X, Yang Q, Wen L, Jiang Y, Zhao Y, et al. MicroRNA-18a enhances the radiosensitivity of cervical cancer cells by promoting radiation-induced apoptosis. Oncol Rep. 2015;33(6):2853–62. doi:10.3892/or.2015.3929.

    CAS  PubMed  Google Scholar 

  22. Sun L, Bian G, Meng Z, Dang G, Shi D, Mi S. MiR-144 inhibits uveal melanoma cell proliferation and invasion by regulating c-Met expression. PLoS One. 2015;10(5):e0124428. doi:10.1371/journal.pone.0124428.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Yu J, Tan Q, Deng B, Fang C, Qi D, Wang R. The microRNA-520a-3p inhibits proliferation, apoptosis and metastasis by targeting MAP3K2 in non-small cell lung cancer. Am J Cancer Res. 2015;5(2):802–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang F, Lou JF, Cao Y, Shi XH, Wang P, Xu J, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med. 2015;47:e162. doi:10.1038/emm.2015.17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu X, Shi H, Liu B, Li J, Liu Y, Yu B. miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer. Acta Biochim Biophys Sin. 2015;47(6):431–40. doi:10.1093/abbs/gmv032.

    Article  PubMed  Google Scholar 

  26. Yang T, Thakur A, Chen T, Yang L, Lei G, Liang Y, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 2015;36(6):4357–65. doi:10.1007/s13277-015-3075-1.

    Article  CAS  PubMed  Google Scholar 

  27. Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X, et al. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. Tumour Biol. 2015;36(8):6497–505. doi:10.1007/s13277-015-3340-3.

    Article  CAS  PubMed  Google Scholar 

  28. Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang L, et al. MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 2015;362(2):208–17. doi:10.1016/j.canlet.2015.03.041.

    Article  CAS  PubMed  Google Scholar 

  29. Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, et al. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med. 2015;4(4):551–64. doi:10.1002/cam4.412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 2010;10(4):435–44. doi:10.1586/erm.10.27.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang Y, Li H, Han J. Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer. Int J Clin Exp Pathol. 2015;8(2):1967–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Yuan B, Liang Y, Wang D, Luo F. MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. Cancer Sci. 2015;106(7):819–24. doi:10.1111/cas.12688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang H, Men CP. Correlation of increased expression of microRNA-155 in bladder cancer and prognosis. Lab Med. 2015;46(2):118–22. doi:10.1309/LMWR9CEA2K2XVSOX.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College, Nankai University, Tianjin, 300071, China

    Yahui Zhang & Yixin Zhang

  2. Department of Orthopedics, Chinese PLA General Hospital, Beijing, 100853, China

    Yanpeng Zhao

  3. Department of Oncology, Chinese PLA General Hospital, Beijing, 100853, China

    Shengjie Sun, Zhefeng Liu & Shunchang Jiao

Authors
  1. Yahui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanpeng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengjie Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhefeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yixin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunchang Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shunchang Jiao.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Zhao, Y., Sun, S. et al. Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients. Tumor Biol. 37, 10155–10160 (2016). https://doi.org/10.1007/s13277-015-4662-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4662-x

Keywords

Search

Navigation